adenoviru
vector
encod
mous
interferon
alpha
subtyp
evalu
efficaci
lethal
vaccinia
viru
wr
strain
respiratori
infect
mice
administ
singl
intranas
treatment
either
prophylact
therapeut
dose
plaqu
form
unitsmous
prophylact
treatment
given
day
prior
infect
protect
anim
death
protect
treatment
given
day
preinfect
minim
weight
loss
occur
infect
surviv
anim
rechalleng
viru
day
primari
infect
protect
death
indic
compromis
immun
respons
initi
infect
postexposur
therapi
given
h
vaccinia
viru
exposur
protect
afford
dose
given
h
wherea
dose
effect
h
comparison
made
abil
given
either
day
prior
infect
inhibit
tissu
viru
titer
lung
infect
paramet
lung
liver
spleen
viru
titer
inhibit
nearli
extent
either
treatment
lung
weight
lung
hemorrhag
score
indic
pneumon
lung
viru
titer
significantli
lower
placebo
group
infect
paramet
treat
mice
nearli
baselin
contrast
viral
titer
lung
infect
paramet
high
placebo
group
day
infect
result
demonstr
longact
prophylact
treatment
capac
combat
vaccinia
viru
infect
citat
smee
df
wong
mh
russel
enni
j
turner
jd
therapi
longterm
prophylaxi
vaccinia
viru
respiratori
infect
mice
adenovirusvector
interferon
alpha
plo
one
threat
use
orthopoxvirus
variola
monkeypox
bioterror
weapon
led
increas
vaccin
particularli
militari
personnel
well
investig
countermeasur
antivir
treatment
infect
number
compound
identifi
exhibit
direct
antivir
activ
relat
poxvirus
anim
model
investig
three
compound
stand
clinic
candid
cidofovir
oral
activ
prodrug
cidofovir
cidofovir
use
emerg
set
treat
vaccin
complic
immun
system
stimul
via
exogen
recombin
interferon
rifn
effect
treat
vaccinia
viru
respiratori
infect
mice
singl
daili
dose
rifna
rifnc
rescu
mice
lethal
administ
day
viru
challeng
reduc
lung
viru
titer
vaccinia
kerat
vacciniainduc
skin
lesion
treat
rifn
topic
inject
respect
monkey
model
success
vaccinia
poxvirus
evolv
comprehens
mechan
antagon
interferon
system
includ
block
ifn
gene
induct
disrupt
extracellular
intracellular
signal
slow
ifn
induc
gene
pkr
oa
activ
treatment
exogen
rifn
compens
host
ifn
gene
suppress
swamp
ifn
bind
protein
must
begin
earli
infect
viru
suppress
activ
antivir
state
interferon
short
halflif
three
hour
requir
frequent
treatment
larg
bolu
dose
result
commensur
advers
effect
often
lead
patientiniti
cessat
treatment
pegyl
rifn
improv
vivo
halflif
allow
weekli
inject
result
reduc
activ
protein
increas
cost
needlefre
singl
dose
drug
capabl
achiev
steadyst
method
deliv
interferon
would
maxim
therapeut
benefit
ifn
minim
bolusinduc
toxic
end
replicationdefici
adenoviru
vector
contain
human
consensu
interferon
alpha
gene
refer
develop
intranas
administr
allow
vector
infect
respiratori
cell
drive
constitut
express
ifn
transgen
secret
fulli
glycosyl
ifn
mous
interferon
result
sustain
ifn
level
complet
protect
mice
lethal
western
equin
enceph
viru
infect
given
intramuscularli
plaqu
form
unit
pfu
mous
day
prior
viru
challeng
venezuelan
equin
enceph
viru
infect
prevent
death
administ
intramuscularli
pfumous
h
prior
infect
given
h
infect
intranasallyadminist
also
use
treat
mice
infect
intranas
sar
viru
result
lethal
respiratori
infect
protect
administ
prophylact
pfu
mous
day
previru
exposur
similar
protect
afford
dose
administ
therapeut
h
infect
adenovir
vector
human
consensu
ifn
recent
use
intranas
treat
hamster
infect
intraperiton
yellow
fever
viru
result
lethal
hepat
infect
protect
death
observ
singl
administr
pfuanim
given
day
day
viru
challeng
demonstr
prophylaxi
therapi
model
treatment
reduc
yellow
fever
viru
titer
liver
spleen
result
decreas
serum
alanin
transaminas
level
herein
evalu
prophylaxi
therapi
vaccinia
viru
wr
strain
respiratori
infect
mice
model
viru
infect
spread
system
includ
tissu
besid
lung
particularli
liver
spleen
increas
lung
weight
lung
hemorrhag
indic
pneumon
hallmark
vaccinia
infect
sever
bodi
weight
loss
result
show
singl
intranas
dose
produc
remark
prolong
prophylact
effect
also
activ
therapeut
experi
conduct
accord
protocol
approv
institut
anim
care
use
committe
utah
state
univers
work
done
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
accord
nation
institut
health
guid
care
use
laboratori
anim
revis
femal
balbc
mice
charl
river
lab
wilmington
weigh
approxim
g
time
first
treatment
use
quarantin
period
anim
randomli
assign
cage
work
anim
perform
biosafeti
level
area
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
adenoviru
vector
mous
interferon
alpha
subtyp
construct
prepar
robert
fitzhenri
vector
laboratori
mcmaster
univers
hamilton
canada
method
prepar
describ
previous
briefli
mous
interferon
alpha
gene
subtyp
clone
replic
defici
vector
delet
gene
delet
amplifi
cell
purifi
cesium
chlorid
gradient
centrifug
stock
solut
store
thaw
ice
dilut
salin
appropri
dose
immedi
prior
singl
administr
gilead
scienc
foster
citi
ca
provid
posit
control
compound
cidofovir
vaccinia
viru
wr
strain
purchas
american
type
cultur
collect
atcc
manassa
va
viru
propag
african
green
monkey
kidney
cell
bioproduct
walkersvil
md
use
studi
mice
anesthet
ketaminexylazin
mgkg
intraperiton
ip
inject
intranas
treatment
intranas
infect
anim
initi
infect
intranas
approxim
pfu
vaccinia
viru
volum
administ
intranas
either
prior
vaccinia
viru
exposur
accord
experiment
schedul
placebotr
mice
given
salin
order
maintain
consist
sinc
intranas
treatment
alter
environ
infect
mice
given
intranas
salin
treatment
given
day
viru
infect
els
addit
placebo
group
use
accommod
deliveri
intranas
liquid
anim
weigh
everi
day
instanc
normal
control
group
untreat
uninfect
mice
maintain
throughout
studi
certain
studi
normal
control
group
infect
viru
end
initi
antivir
studi
serv
infect
control
reinfect
treat
mice
surviv
primari
infect
reinfect
day
approxim
pfu
unit
vaccinia
viru
volum
dose
larger
primari
infect
account
increas
age
mice
older
mice
less
suscept
vaccinia
infect
agematch
normal
control
anim
infect
first
time
viru
challeng
surviv
bodi
weight
group
determin
period
separ
anim
maintain
determin
tissu
viru
titer
lung
hemorrhag
score
lung
weight
group
infect
mice
per
day
sacrif
remov
tissu
lung
given
hemorrhag
score
color
chang
pink
plum
occur
region
lung
rather
gradual
entir
lung
rang
entir
lung
affect
lung
spleen
liver
snout
weigh
prior
homogen
releas
infecti
viru
titrat
homogen
soft
tissu
done
ml
cell
cultur
medium
use
stomach
snout
ground
ml
medium
use
steril
mortar
pestl
sampl
serial
dilut
increment
plaqu
titrat
micropl
vero
cell
plaqu
stain
three
day
crystal
violet
buffer
formalin
plaqu
count
aid
light
box
plaqu
number
convert
pfu
per
gram
infect
tissu
initi
survivor
number
compar
multipl
group
chi
squar
analysi
statist
signific
found
survivor
number
evalu
use
twotail
fisher
exact
test
differ
mean
day
death
tissu
viru
titer
lung
weight
lung
hemorrhag
score
statist
analyz
use
twotail
mannwhitney
utest
analys
perform
use
instath
comput
softwar
program
graphpad
softwar
san
diego
ca
compar
treat
placebo
group
shortterm
prophylact
activ
administ
variou
intranas
dose
one
day
prior
viru
challeng
present
tabl
uniformli
protect
lethal
vaccinia
challeng
dose
pfuanim
protect
effect
attribut
mifn
transgen
empti
adenoviru
vector
protect
produc
similar
complet
mortal
placebo
control
cidofovir
posit
control
compound
also
protect
mgkgday
administ
intraperiton
rout
start
day
postinfect
tabl
also
show
effect
treatment
cidofovir
lung
infect
paramet
doserespons
effect
lung
viru
titer
seen
treatment
highest
dose
caus
nearli
reduct
lung
viru
titer
dose
pfumous
reduc
viru
titer
respect
three
treatment
significantli
reduc
lung
weight
lung
hemorrhag
score
contrast
cidofovir
treatment
caus
reduct
viru
titer
protect
lung
virusinduc
patholog
lung
viru
titer
lung
weight
also
intermedi
dosag
group
neither
control
adenoviru
empti
vector
inhibit
lung
infect
paramet
measur
window
prophylact
activ
pfumous
administ
variou
time
prior
viru
infect
tabl
first
experi
singl
dose
protect
administ
day
day
previru
exposur
mean
bodi
weight
cours
primari
infect
present
figur
treatment
larg
protect
anim
weight
loss
slight
drop
weight
occur
day
follow
intranas
exposur
viru
mice
back
initi
start
weight
day
seven
placebotr
anim
surviv
infect
differ
tabl
anim
surviv
like
occur
mice
time
infect
day
older
suscept
anim
infect
diminish
age
sever
weight
loss
placebo
group
persist
day
infect
time
seven
anim
surviv
infect
began
recov
bodi
weight
surviv
mice
experi
reinfect
higher
challeng
vaccinia
viru
origin
given
anim
surviv
rechalleng
tabl
infect
agematch
mice
result
expect
mortal
weight
loss
occur
treat
group
much
less
sever
infect
mice
figur
rebound
weight
loss
reinfect
fastest
placebo
group
group
contain
serious
afflict
anim
primari
infect
thu
would
expect
robust
immun
respons
treat
anim
get
sick
base
upon
success
extend
prophylaxi
day
preinfect
second
experi
tabl
initi
use
start
time
earli
day
viru
challeng
protect
administ
day
protect
given
shorter
time
point
day
viru
challeng
dose
higher
given
experi
see
footnot
b
tabl
result
placebotr
anim
experi
die
primari
infect
minim
weight
loss
occur
group
treat
prophylact
figur
decreas
bodi
weight
group
primarili
seen
day
infect
nadir
day
surviv
mice
treat
second
experi
tabl
reinfect
higher
challeng
vaccinia
viru
anim
surviv
infect
agematch
mice
result
mortal
weight
loss
occur
treat
group
minim
occur
day
figur
contrast
rapid
weight
declin
infect
mice
bodi
weight
reinfect
similar
group
slightli
less
rapid
recoveri
bodi
weight
day
seen
group
treat
prophylact
day
compar
treat
group
viral
titer
variou
tissu
determin
mice
treat
either
day
day
prior
infect
lung
viru
titer
treat
group
least
less
placebo
treat
mice
figur
liver
spleen
viru
titer
near
level
detect
anim
treat
increas
time
placebo
figur
snout
viru
titer
treat
group
significantli
less
placebo
day
day
figur
compar
viru
titer
day
group
day
group
amount
detect
viru
nearli
equival
lung
liver
spleen
differ
observ
snout
viru
titer
two
group
due
variabl
differ
statist
signific
lung
weight
lung
hemorrhag
score
determin
infect
mice
parallel
determin
viral
titer
lung
weight
treat
anim
near
normal
wherea
day
placebo
exhibit
larg
increas
lung
weight
figur
similarli
lung
score
near
normal
two
group
treat
sever
day
placebo
group
figur
extent
inhibit
lung
intranas
treatment
pfumous
given
one
time
indic
day
prior
viru
exposur
experi
primari
intranas
challeng
pfu
viru
sinc
challeng
dose
fail
caus
mortal
mice
age
suscept
infect
wane
primari
viru
challeng
dose
increas
pfu
viru
experi
reinfect
set
mice
perform
intranas
pfu
viru
data
accompani
tabl
thu
initi
number
mice
per
group
figur
correspond
total
number
per
group
tabl
diseas
day
group
compar
seen
day
group
result
experi
indic
extrem
longact
prophylact
activ
vaccinia
viru
infect
mice
anim
treat
day
prior
infect
hint
wane
activ
sinc
one
anim
die
infect
group
two
differ
dose
administ
infect
combat
vaccinia
viru
infect
preliminari
studi
low
dose
pfumous
given
h
infect
provid
protect
lethal
infect
data
shown
howev
higher
dose
pfumous
protect
administ
either
h
infect
tabl
pfumous
dose
protect
given
hour
protect
administ
hour
surviv
time
lower
dosag
group
receiv
treatment
hour
significantli
increas
rel
placebo
control
cidofovir
protect
administ
mgkgday
two
day
start
h
bodi
weight
chang
treatment
surviv
cours
infect
shown
figur
cidofovir
weight
loss
treat
mice
increas
longer
delay
commenc
treatment
anim
regain
prechalleng
weight
day
experi
given
weight
loss
group
delay
treatment
would
like
result
mortal
mice
treat
daili
cidofovir
start
postvaccinia
challeng
lost
less
weight
studi
singl
intranas
dose
found
exhibit
potent
prophylact
activ
endur
least
day
endpoint
durat
protect
could
project
treatment
day
result
one
death
intranas
treatment
pfumous
given
one
time
indic
day
prior
intranas
viru
exposur
pfu
survivor
placebo
group
day
data
determin
experi
conduct
concurr
second
experi
tabl
data
point
repres
mean
five
anim
per
group
caus
minim
weight
loss
infect
inde
weight
loss
infect
day
treatment
group
equival
day
treatment
group
investig
paramet
infect
tissu
viru
titer
lung
weight
lung
hemorrhag
score
reveal
inhibit
paramet
day
treatment
quit
compar
day
treatment
prophylaxi
start
day
infect
could
effect
achiev
dose
pfumous
extend
prophylaxi
day
preinfect
investig
dose
investig
shown
mous
human
construct
activ
prophylact
kumaki
et
al
show
protect
sar
infect
mice
dose
given
day
time
point
assess
thu
possibl
prophylaxi
earlier
day
would
protect
sar
infect
yellow
fever
viru
infect
hamster
effect
given
day
prior
infect
day
breadth
viral
efficaci
indic
potenti
function
truli
broadspectrum
antivir
remark
effect
mice
vaccinia
viru
infect
given
nearli
two
month
prior
viru
exposur
indic
ifn
induc
longterm
antivir
state
complet
protect
singl
dose
extend
prophylaxi
appear
exist
absenc
measur
serum
ifn
level
sinc
wu
et
al
abl
detect
interferon
alpha
protein
mice
treat
intramuscularli
h
day
time
investig
studi
rais
number
import
question
rel
long
act
protect
effect
vaccinia
viru
infect
mice
question
much
interferon
produc
long
produc
cell
respons
produc
ask
current
investig
alreadi
shown
interferon
success
produc
vector
administ
intramuscularli
mice
protein
detect
serum
work
also
know
level
interferon
rise
quickli
within
h
transient
high
come
within
sever
day
infer
interferon
protein
deliv
success
lung
nostril
sinc
confirm
separ
studi
unpublish
given
protect
last
longer
previous
measur
level
interferon
protein
persist
assum
interferon
activ
immunolog
cascad
protect
anim
infect
induc
antivir
state
thorough
investig
induc
gene
length
induct
local
induct
plan
beyond
scope
studi
choic
intranas
rout
administr
import
rout
demonstr
bypass
preexist
immun
adenoviru
vector
intranas
deliveri
also
less
invas
easier
administ
larg
number
patient
event
mass
infect
due
natur
outbreak
intent
releas
adenoviru
select
vector
interferon
due
rapid
infect
breadth
human
safeti
data
facil
intranas
administr
administ
intranas
rout
alreadi
shown
effect
treatment
sar
coronaviru
respiratori
infect
mice
first
descript
adenovir
vector
interferon
alpha
use
rout
prevent
treat
vaccinia
viru
infect
limit
therapeut
window
time
exist
treat
vaccinia
viru
infect
interferonbas
drug
like
achiev
treatment
higher
dose
need
prophylaxi
inde
low
dose
pfumous
effect
prophylact
effect
administ
even
h
infect
higher
dose
pfu
mous
requir
full
protect
lethal
given
h
howev
consider
bodi
weight
loss
result
due
infect
figur
singl
dose
administ
h
effect
daili
dose
mgkg
cidofovir
act
directli
vaccinia
inhibit
replic
may
due
part
lag
time
administr
product
therapeut
level
ifn
within
h
secondli
situ
produc
ifn
must
overcom
high
level
ifn
system
regul
caus
establish
vaccinia
infect
demonstr
investig
effect
treatment
given
within
day
viru
exposur
well
advector
ifn
protect
infect
anim
depend
upon
viru
virul
includ
number
express
differ
ifn
system
antagonist
howev
treatment
efficaci
unrel
virus
indic
real
potenti
broad
spectrum
antivir
extrapol
treatment
window
clinic
scenario
may
signific
studi
antivir
activ
depend
amount
administ
case
publish
studi
unrel
virus
product
steadyst
level
interferon
may
bypass
need
bolu
dose
associ
tradit
interferon
treatment
thu
reduc
toxic
side
effect
nevertheless
safeti
consider
eventu
human
use
safeti
toxicolog
studi
ongo
need
determin
long
ifninduc
antivir
state
persist
effect
treat
individu
first
studi
demonstr
surviv
mice
treat
protect
reinfect
viru
surpris
treatment
complet
prevent
vaccinia
viru
product
lung
snout
anim
figur
thu
drive
acquir
immun
respons
verac
immun
respons
treat
anim
like
weaker
would
sever
infect
mice
base
upon
weight
comparison
surviv
placebo
figur
assum
adequ
safeti
profil
one
envis
use
mean
quickli
provid
signific
protect
first
respond
medic
chain
personnel
confront
deliber
releas
variola
monkeypox
viru
environ
even
infect
treat
individu
could
still
acquir
immun
viru
demonstr
present
studi
thu
render
vaccin
futur
exposur
intranas
method
deliveri
facilit
rapid
prophylaxi
peopl
enter
suspect
poxviru
environ
moreov
potenti
treat
larg
number
unrel
virus
simultan
current
treatment
